8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549
                                  ------------
                                    FORM 8-K
                                  ------------
                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       The Securities Exchange Act of 1934

                Date of Report (Date of Earliest Event Reported):
                               September 23, 2003

                           USANA HEALTH SCIENCES, INC.

             (Exact name of registrant as specified in its charter)

                           Commission File No. 0-21116

                  Utah                                    87-0500306

     (State or other jurisdiction of             (IRS Employer Identification

             incorporation)                                 Number)

                           3838 West Parkway Boulevard
                           Salt Lake City, Utah 84120
               (Address of principal executive offices, Zip Code)

       Registrant's telephone number, including area code: (801) 954-7100

   Former name or former address, if changed since last report: Not Applicable



Item 9. Regulation FD Disclosure

On September 23, 2003, USANA Health Sciences, Inc. issued a press release
updating its estimate for sales and earnings per share for the third quarter of
fiscal 2003. The press release dated September 23, 2003 updated the previous
sales and earnings per share guidance provided by the company in a press release
dated July 15, 2003, previously furnished on Form 8-K. A copy of the press
release dated September 23, 2003 is furnished herewith as Exhibit 99.1 to this
Form 8-K and is incorporated herein by reference. The company will also post the
press release on its corporate website, www.usanahealthsciences.com under the
"investor relations" link.

The information in this Current Report is being furnished and shall not be
deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act
of 1934, as amended, or otherwise subject to the liabilities of that Section.
The information in this Current Report shall not be incorporated by reference
into any registration statement or other document pursuant to the Securities Act
of 1933, as amended. The furnishing of the information in this Current Report is
not intended to, and does not, constitute a representation that such furnishing
is required by Regulation FD or that the information this Current Report
contains is material investor information that is not otherwise publicly
available.
                                       2



                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                      USANA HEALTH SCIENCES, INC.




                                      By:  /s/ Gilbert A. Fuller
                                           ---------------------
                                      Gilbert A. Fuller, Chief Financial Officer

Date: September 23, 2003

                                       3

EX-99

                                                                Exhibit 99.1

USANA Expects Earnings to Significantly Exceed Earlier Guidance; Sales
In-line with Prior Forecast

    SALT LAKE CITY--(BUSINESS WIRE)--Sept. 23, 2003--USANA Health
Sciences Inc. (NASDAQ: USNA) announced today that it now expects
earnings per share for the third quarter to exceed the company's
earlier guidance and looks for sales to be in-line with its prior
forecast.
    The company continues to expect that sales for the quarter ending
Sept. 27, 2003 will approach $52 million. However, earnings per share
are expected to be approximately $0.54, of which about $0.03 would be
attributable to an adjustment of the company's effective tax rate for
2003. Initial guidance for the third quarter had earnings per share in
the range of $0.43 to $0.45.
    Gilbert A. Fuller, chief financial officer, commented, "We are
pleased with the strong earnings and sales growth we are experiencing
this quarter. We continue to see operating margin improvements as we
leverage the physical and information technology infrastructure
investments made over the last several years. Earnings per share and
sales for the quarter are expected to be up approximately 145% and
48%, respectively, on a year-over-year basis. The third quarter of
2003 will represent the seventh consecutive quarter in which we have
more than doubled the prior year EPS mark."
    USANA plans to announce its third quarter earnings along with new
guidance for the fourth quarter and for the fiscal year 2004, on Oct.
14, 2003; executives will hold a conference call with investors on
Oct. 15, 2003, to provide an update.
    USANA develops and manufactures high-quality nutritionals,
personal care, and weight management products that are sold directly
to Preferred Customers and Associates throughout the United States,
Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea
and the United Kingdom. More information on USANA can be found at
http://www.usanahealthsciences.com.

    This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act and Section 21E of the
Securities Exchange Act. Actual results could differ materially from
those projected in the forward-looking statements, which involve a
number of risks and uncertainties, including reliance upon the
company's independent Associate network, government regulation of
products, manufacturing and marketing, the possible continued spread
of severe acute respiratory syndrome (SARS) in Asia, and risks
associated with international expansion. Those statements include the
statements that (1) "The company continues to expect that sales for
the quarter ending Sept. 27, 2003 will approach $52 million," (2)
"earnings per share are expected to be approximately $0.54," (3)
"about $0.03 would be attributable to an adjustment of the company's
effective tax rate for 2003," and (4) "Earnings per share and sales
for the quarter are expected to be up approximately 145% and 48%,
respectively, on a year-over-year basis." The contents of this release
should be considered in conjunction with the warnings and cautionary
statements contained in USANA's most recent filings with the
Securities and Exchange Commission on Forms 10-Q and 10-K.

    CONTACT: USANA Health Sciences Inc., Salt Lake City
             Riley Timmer, 801-954-7100
             investor.relations@us.usana.com